Expression of mTOR in normal and pathological conditions
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.21/16353 |
Resumo: | The H&TRC authors gratefully acknowledge the FCT/MCTES national support through the UIDB/05608/2020 and UIDP/05608/2020. This work was part of the IPL/2021/GATumor_ESTeSL project. |
id |
RCAP_b2bd86a6dc1711a7d53cbe6b90df02e6 |
---|---|
oai_identifier_str |
oai:repositorio.ipl.pt:10400.21/16353 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Expression of mTOR in normal and pathological conditionsmTOR biomarkemTOR expressionmTOR expression cancermTOR expression diseasemTOR mRNA stabilitymTOR transcriptional regulationmTOR translation regulationIPL/2021/GATumor_ESTeSLFCT_UIDB/05608/2020FCT_UIDP/05608/2020The H&TRC authors gratefully acknowledge the FCT/MCTES national support through the UIDB/05608/2020 and UIDP/05608/2020. This work was part of the IPL/2021/GATumor_ESTeSL project.The mechanistic/mammalian target of rapamycin (mTOR), a protein discovered in 1991, integrates a complex pathway with a key role in maintaining cellular homeostasis. By comprising two functionally distinct complexes, mTOR complex 1 (mTORC1) and mTORC2, it is a central cellular hub that integrates intra- and extracellular signals of energy, nutrient, and hormone availability, modulating the molecular responses to acquire a homeostatic state through the regulation of anabolic and catabolic processes. Accordingly, dysregulation of the mTOR pathway has been implicated in a variety of human diseases. While major advances have been made regarding the regulators and effectors of the mTOR signaling pathway, insights into the regulation of mTOR gene expression are beginning to emerge. Here, we present the currently available data regarding the mTOR expression regulation at the level of transcription, translation, and mRNA stability and systematize the current knowledge about the fluctuations of mTOR expression observed in several diseases, both cancerous and non-cancerous. In addition, we discuss whether mTOR expression changes can be used as a biomarker for diagnosis, disease progression, prognosis, and/or response to therapeutics. We believe that our study will contribute to the implementation of new disease biomarkers based on mTOR as it gives an exhaustive perspective on the regulation of mTOR gene expression in both normal and pathological conditions.Springer NatureRCIPLMarques-Ramos, AnaCervantes, Renata2023-08-01T11:09:33Z2023-072023-07-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/16353engMarques-Ramos A, Cervantes R. Expression of mTOR in normal and pathological conditions. Mol Cancer. 2023;22(1):112.10.1186/s12943-023-01820-zinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T10:14:57Zoai:repositorio.ipl.pt:10400.21/16353Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:23:54.434655Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Expression of mTOR in normal and pathological conditions |
title |
Expression of mTOR in normal and pathological conditions |
spellingShingle |
Expression of mTOR in normal and pathological conditions Marques-Ramos, Ana mTOR biomarke mTOR expression mTOR expression cancer mTOR expression disease mTOR mRNA stability mTOR transcriptional regulation mTOR translation regulation IPL/2021/GATumor_ESTeSL FCT_UIDB/05608/2020 FCT_UIDP/05608/2020 |
title_short |
Expression of mTOR in normal and pathological conditions |
title_full |
Expression of mTOR in normal and pathological conditions |
title_fullStr |
Expression of mTOR in normal and pathological conditions |
title_full_unstemmed |
Expression of mTOR in normal and pathological conditions |
title_sort |
Expression of mTOR in normal and pathological conditions |
author |
Marques-Ramos, Ana |
author_facet |
Marques-Ramos, Ana Cervantes, Renata |
author_role |
author |
author2 |
Cervantes, Renata |
author2_role |
author |
dc.contributor.none.fl_str_mv |
RCIPL |
dc.contributor.author.fl_str_mv |
Marques-Ramos, Ana Cervantes, Renata |
dc.subject.por.fl_str_mv |
mTOR biomarke mTOR expression mTOR expression cancer mTOR expression disease mTOR mRNA stability mTOR transcriptional regulation mTOR translation regulation IPL/2021/GATumor_ESTeSL FCT_UIDB/05608/2020 FCT_UIDP/05608/2020 |
topic |
mTOR biomarke mTOR expression mTOR expression cancer mTOR expression disease mTOR mRNA stability mTOR transcriptional regulation mTOR translation regulation IPL/2021/GATumor_ESTeSL FCT_UIDB/05608/2020 FCT_UIDP/05608/2020 |
description |
The H&TRC authors gratefully acknowledge the FCT/MCTES national support through the UIDB/05608/2020 and UIDP/05608/2020. This work was part of the IPL/2021/GATumor_ESTeSL project. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-08-01T11:09:33Z 2023-07 2023-07-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.21/16353 |
url |
http://hdl.handle.net/10400.21/16353 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Marques-Ramos A, Cervantes R. Expression of mTOR in normal and pathological conditions. Mol Cancer. 2023;22(1):112. 10.1186/s12943-023-01820-z |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Springer Nature |
publisher.none.fl_str_mv |
Springer Nature |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1817554350738767872 |